Outlook Therapeutics CFO reports no share holdings

Outlook Therapeutics, Inc. (OTLK) reports that its Chief Financial Officer, Kevin Michael Lundquist, has filed an initial statement of beneficial ownership on Form 3.

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. (OTLK) reports that its Chief Financial Officer, Kevin Michael Lundquist, has filed an initial statement of beneficial ownership on Form 3. The filing does not list any equity holdings, derivative positions, or transactions in Outlook Therapeutics securities by the reporting person.

Key Figures

Reported buy transactions: 0 transactions Reported sell transactions: 0 transactions Reported holdings entries: 0 entries

3 metrics

Reported buy transactions 0 transactions BuyCount in the Form 3 transaction summary

Reported sell transactions 0 transactions SellCount in the Form 3 transaction summary

Reported holdings entries 0 entries HoldingEntries in the Form 3 transaction summary

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 for OTLK disclose about Kevin Michael Lundquist?

It states that Kevin Michael Lundquist is the Chief Financial Officer of Outlook Therapeutics, Inc. and serves as the reporting person for this initial statement of beneficial ownership of securities.

Are any Outlook Therapeutics (OTLK) shares reported as owned on this Form 3?

No. The Form 3 reports no equity holdings for the reporting person, with no non-derivative or derivative securities positions listed.

Does the OTLK Form 3 show any recent insider transactions?

No. The Form 3 shows no reported transactions in Outlook Therapeutics securities, with zero buy, sell, acquisition, or disposition entries summarized.

Is there any Rule 10b5-1 trading plan information in this OTLK Form 3?

No Rule 10b5-1 trading plan is reported in connection with this Form 3; the summary shows no transactions that would be associated with such a plan.

What is the significance of a Form 3 with no holdings for OTLK?

A Form 3 with no reported holdings indicates that, as of the reporting date, the insider did not report beneficial ownership of Outlook Therapeutics securities or any related derivative positions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:32 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Lundquist Kevin Michael

(Last) (First) (Middle)

111 SOUTH WOOD AVENUE

UNIT 100

(Street)

ISELIN NEW JERSEY 08830

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/01/2026

3. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jennifer Couture, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)